Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2022-02-04 Major Shareholding Noti…
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-04 English
License with Intima Bioscience
Regulatory Filings Classification · 1% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) announcing a strategic platform license agreement between MaxCyte, Inc. and Intima Bioscience. It details a business partnership and commercial agreement rather than a financial report, governance update, or shareholder meeting material. Since it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category.
2022-02-01 English
FORM 8-K
Regulatory Filings
2022-01-24 English
Preliminary Unaudited Q4 & FY 2021 Revenue Results
Earnings Release Classification · 1% confidence The document is a press release from MaxCyte, Inc. announcing preliminary, unaudited financial results for the fourth quarter and full year 2021. It provides key highlights such as revenue growth, installed base metrics, and strategic platform license (SPL) updates. Because this is an initial announcement of financial results rather than a full quarterly or annual report, it is classified as an Earnings Release (ER). Q4 2021
2022-01-24 English
Holdings in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by BlackRock, Inc. regarding their shareholding in MaxCyte, Inc. This is a classic regulatory disclosure document used to notify the market and the issuer when a shareholder crosses a specific voting rights threshold. This fits the definition of a 'Major Shareholding Notification'.
2021-12-29 English
Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding 'Total Voting Rights'. It details the issuance of new common stock following the exercise of share options and provides the updated total issued stock capital to be used by shareholders for notification calculations. This falls under the category of share capital changes and voting rights updates, which is best classified as 'Share Issue/Capital Change' (SHA).
2021-12-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.